Skip to content

Full Spectrum Hemp Observational Study

Acne Vulgaris Blemish Full Spectrum Hemp Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04730414
Enrollment
50
Registered
2021-01-29
Start date
2021-02-28
Completion date
2021-12-31
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris, Acne Vulgaris Superficial Mixed Comedonal and Inflammatory

Keywords

Blemishes

Brief summary

In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

Detailed description

Charlotte's Web Full spectrum hemp blemish product will contain a mere 0.018% THC and will therefor not impart a psychotic affect. Hemp has been shown to be well tolerated in humans and has a very acceptable dosage, efficacy and safety profile when topically applied. The FDA has labeled hemp as Generally Regarded As Safe (GRAS) and as such reduces the risk of severe adverse reactions to the subject. Benefits of hemp blemish 'cream is that it has been formulated in such a way as to promote natural skin balance, and may eliminate skin dryness, inflammation, hyperpigmentation, and scaring. The primary objective and endpoint of the study is to obtain total eradication of the blemish eruptions. The secondary objective and endpoints is the continued use of the hemp product will continue to prevent further blemish eruptions and provide other skin benefits especially reducing the propensity to scar.

Interventions

DRUGFull-spectrum hemp (0.018% THC)

Topical Application

Sponsors

Charlotte's Web, Inc
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Male/female * Diagnosed acne vulgaris * Not on current acne treatment(s) or off current treatment for 2 weeks * 13-70 yrs old

Exclusion criteria

* Not willing to stop current acne treatment(s) * males that present with facial hair * active TB, HIV or hepatitis * pregnant or lactating females

Design outcomes

Primary

MeasureTime frameDescription
Facial Blemishes2-3 monthsTotal eradication of of acne vulgaris/blemishes with reduction of inflammation

Secondary

MeasureTime frameDescription
Improvement of overall skin tone2-3-6 monthsRestoration of natural skin balance to provide secondary benefits for other skin maladies.

Other

MeasureTime frameDescription
Social Benefits of Full Spectrum Hemp2-3-6 monthsProvide a significant quality of life in social settings

Contacts

Primary ContactSherry Bradford, PhD
sherry.bradford.ctr@charlottesweb.com7168607800
Backup ContactJeff Lokken, BS, MS
jeff.lokken@charlottesweb.com2129339223

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026